Medicine & Life Sciences
Hepacivirus
100%
Hepatitis C
99%
Hepatitis B
60%
Fibrosis
48%
Hepatitis B virus
47%
Hepatocellular Carcinoma
47%
Liver
46%
telaprevir
41%
Liver Diseases
34%
Liver Transplantation
33%
Sofosbuvir
26%
Virus Diseases
26%
Hepatitis
24%
Therapeutics
23%
Chronic Hepatitis C
23%
HIV
19%
Liver Cirrhosis
19%
Sustained Virologic Response
16%
Odds Ratio
16%
Infections
15%
Liver Neoplasms
15%
Monoclonal Gammopathy of Undetermined Significance
15%
Antiviral Agents
15%
Ribavirin
14%
Coronavirus
14%
Coinfection
13%
Chronic Disease
13%
Telemedicine
12%
Patient Reported Outcome Measures
11%
Non-alcoholic Fatty Liver Disease
11%
Population
11%
Transplant Recipients
11%
Registries
11%
Delivery of Health Care
11%
Costs and Cost Analysis
11%
Confidence Intervals
10%
Multiple Myeloma
10%
Incidence
10%
Mortality
10%
Cohort Studies
10%
Simeprevir
10%
Primary Health Care
10%
Genotype
9%
2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole
9%
Opioid Analgesics
9%
MK-5172
9%
Chemical and Drug Induced Liver Injury
9%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
9%
Gastroenterologists
9%
Chronic Hepatitis B
8%
Social Sciences
contagious disease
76%
immigrant
24%
cancer
13%
HBV
9%
cost-reimbursement
9%
group education
7%
health
7%
case managers
6%
management
6%